Copperwynd Financial LLC Has $1.67 Million Stock Position in Merck & Co., Inc. $MRK

Copperwynd Financial LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 2.4% during the 2nd quarter, Holdings Channel reports. The fund owned 21,144 shares of the company’s stock after buying an additional 487 shares during the period. Copperwynd Financial LLC’s holdings in Merck & Co., Inc. were worth $1,674,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Peoples Financial Services CORP. increased its position in Merck & Co., Inc. by 0.5% in the second quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after buying an additional 122 shares during the last quarter. McLean Asset Management Corp increased its position in Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after buying an additional 125 shares during the last quarter. Cora Capital Advisors LLC increased its position in Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock worth $423,000 after buying an additional 125 shares during the last quarter. Foundation Wealth Management LLC PA increased its position in Merck & Co., Inc. by 2.4% in the first quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock worth $481,000 after buying an additional 127 shares during the last quarter. Finally, Saiph Capital LLC increased its position in Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after buying an additional 128 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $86.39 on Thursday. The stock has a market cap of $215.78 billion, a PE ratio of 13.31, a price-to-earnings-growth ratio of 0.90 and a beta of 0.37. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $111.58. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The stock has a fifty day moving average of $83.15 and a 200-day moving average of $81.56.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Investors of record on Monday, September 15th were given a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a yield of 3.8%. The ex-dividend date was Monday, September 15th. Merck & Co., Inc.’s payout ratio is presently 49.92%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MRK. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company decreased their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Finally, Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $104.31.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.